tanespimycin (BMS-722782) / BMS 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tanespimycin (BMS-722782) / BMS
2007-004138-17: Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse

Ongoing
3
466
Europe
Tanespimycin, Velcade, KOS-953 or BMS-722782, Suspension for injection, Powder for solution for injection, Velcade®
Bristol Myers Squibb International Corporation, KOSAN BIOSCIENCES, INC.
Patients with multiple myeloma in first relapse after failure of previous anti-cancer therapy and/or bone marrow transplantation
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tanespimycin (BMS-722782) / BMS
2007-004138-17: Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse

Ongoing
3
466
Europe
Tanespimycin, Velcade, KOS-953 or BMS-722782, Suspension for injection, Powder for solution for injection, Velcade®
Bristol Myers Squibb International Corporation, KOSAN BIOSCIENCES, INC.
Patients with multiple myeloma in first relapse after failure of previous anti-cancer therapy and/or bone marrow transplantation
 
 

Download Options